Adverum Biotechnologies provides update on A1AT Deficiency program
Adverum Biotechnologies provided an update on its development program for ADVM-043, a novel gene therapy for Alpha-1 Antitrypsin, or A1AT, Deficiency, a rare genetic disorder that may result in serious respiratory and liver disease. Adverum has decided to upgrade the ADVM-043 manufacturing process by implementing its proprietary baculovirus-based production system and plans to transfer the third-party contract manufacturing for ADVM-043 to a large-scale contract manufacturer. This upgrade is designed to increase the production scale, and comply with industry standards so that the same production process is used from clinical trials through commercial stage. The company now expects to begin enrolment of patients in the Phase 1/2 clinical trial for ADVM-043 in the fourth quarter of 2017.